QIAGEN

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell QIAGEN and other ETFs, options, and stocks.

About QGEN

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Its sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. 

CEO
Thierry L. Bernard
CEOThierry L. Bernard
Employees
5,654
Employees5,654
Headquarters
Venlo, Limburg
HeadquartersVenlo, Limburg
Founded
1996
Founded1996
Employees
5,654
Employees5,654

QGEN Key Statistics

Market cap
8.48B
Market cap8.48B
Price-Earnings ratio
21.45
Price-Earnings ratio21.45
Dividend yield
0.63%
Dividend yield0.63%
Average volume
3.73M
Average volume3.73M
High today
$41.78
High today$41.78
Low today
$40.87
Low today$40.87
Open price
$41.76
Open price$41.76
Volume
2.17M
Volume2.17M
52 Week high
$57.82
52 Week high$57.82
52 Week low
$32.53
52 Week low$32.53

Stock Snapshot

QIAGEN(QGEN) stock is priced at $41.15, giving the company a market capitalization of 8.48B. It carries a P/E multiple of 21.45 and pays a dividend yield of 0.63%.

On 2026-07-17, QIAGEN(QGEN) stock traded between a low of $40.87 and a high of $41.78. Shares are currently priced at $41.15, which is +0.7% above the low and -1.5% below the high.

QIAGEN(QGEN) shares are trading with a volume of 2.17M, against a daily average of 3.73M.

During the past year, QIAGEN(QGEN) stock moved between $32.53 at its lowest and $57.82 at its peak.

During the past year, QIAGEN(QGEN) stock moved between $32.53 at its lowest and $57.82 at its peak.

QGEN News

TipRanks 5h
BlackRock Discloses Significant Stake in Qiagen

TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE. R...

Simply Wall St 16h
Is Rising Cyclospora Testing Demand Reframing Qiagen’s Infectious Disease Strategy?

Earlier this month, QIAGEN highlighted how its FDA-cleared QIAstat-Dx Gastrointestinal Panel 2 and broader molecular testing portfolio are being used to detect...

Is Rising Cyclospora Testing Demand Reframing Qiagen’s Infectious Disease Strategy?
TipRanks 3d
Qiagen price target raised to $44 from $40 at TD Cowen

TD Cowen raised the firm’s price target on Qiagen (QGEN) to $44 from $40 and keeps a Hold rating on the shares. The firm adjusted targets in the tools space as...

Analyst ratings

55%

of 22 ratings
Buy
45.5%
Hold
54.5%
Sell
0%

More QGEN News

Investing.com 3d
Qiagen launches bloodstream infection test panel in Europe - Investing.com

...

Qiagen launches bloodstream infection test panel in Europe - Investing.com
TipRanks 3d
Qiagen expands QIAstat-Dx bloodstream infection testing menu in Europe

Qiagen (QGEN) announced the launch of the CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel, establishing a comprehensive bloodstream infection testing offeri...

Simply Wall St 4d
Is Qiagen A Bargain After Takeover Interest Reignited Valuation Questions?

Qiagen (QGEN) is back in focus after reports of early takeover interest from private equity firms, including EQT, Advent and KKR, with some potential bidders re...

Is Qiagen A Bargain After Takeover Interest Reignited Valuation Questions?

People also own

Based on the portfolios of people who own QGEN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.